HyBryte Study Shows 60% Success in CTCL, Outperforming Comparator with Favorable Safety
SNGX is trading near its 52-week low of $1 (15% above the low).
Summary
Soligenix announced the publication of positive results from its comparability study for HyBryte(TM) in treating cutaneous T-cell lymphoma (CTCL). The study demonstrated that 60% of HyBryte-treated patients achieved treatment success, significantly outperforming Valchlor at 20%, with no treatment-related adverse events reported for HyBryte. This is a highly material development for Soligenix, a micro-cap company that recently issued a going concern warning in its 10-K due to increased losses and insufficient cash. Positive clinical data for a key asset like HyBryte is critical for the company's ability to attract partners or secure financing, which is essential for its survival and progression towards potential commercialization. Traders will closely monitor for subsequent regulatory submissions or strategic partnership announcements.
At the time of this announcement, SNGX was trading at $1.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.6M. The 52-week trading range was $1.00 to $6.23. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: FinanceWire.